SAHA induce hippo pathway in CCA cells without increasing cell proliferation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cholangiocarcinoma (CCA) is a bile duct cancer with poor prognosis due to metastasis.
• There is a critical need for novel therapeutic strategies for CCA.
• This study investigated the effects of SAHA, a histone deacetylase (HDAC) inhibitor, on the TFK-1 extrahepatic CCA cell line.

Purpose of the Study:

• To evaluate the impact of SAHA on cholangiocarcinoma cell viability and cell cycle progression.
• To assess the effects of SAHA on the expression of key proteins and genes involved in cancer progression, including YAP, TAZ, TGF-β, TEAD, TIMP2, and TIMP3.
• To explore the potential of SAHA as a therapeutic agent for extrahepatic cholangiocarcinoma.

Main Methods:

• Cell viability and cell cycle analysis using Muse Cell Analyzer.
• Protein expression levels of YAP, TAZ, and TGF-β determined by Western blotting.
• Gene expression analysis of TEAD (1-3), TIMP2, and TIMP3 using real-time PCR.

Main Results:

• SAHA demonstrated antiproliferative effects, reducing TFK-1 cell viability and inducing G0/G1 cell cycle arrest.
• SAHA treatment led to increased expression of YAP, TAZ, TGF-β proteins, and TEAD (1-3) genes.
• SAHA showed a trend towards reduced TIMP2 and TIMP3 expression, though not statistically significant.

Conclusions:

• While SAHA exhibits antiproliferative activity, the observed increase in aggressive markers suggests potential drug resistance or selection for more aggressive phenotypes.
• Caution is advised regarding the use of SAHA for cholangiocarcinoma treatment due to these complex effects.
• Further investigation is warranted to understand the dual effects of SAHA and its therapeutic potential in CCA.